Virology
“Paxlovid Rebound” Is Just COVID Rebound
By Gertrud U. Rey | | Basic virology, Gertrud Rey
by Gertrud U. Rey The antiviral drug Paxlovid is highly effective at inhibiting SARS-CoV-2 replication and reducing symptoms associated with COVID-19. Nevertheless, there have recently been numerous reports of recurrence of positive tests and symptoms after completing treatment with Paxlovid, leading some to infer that the drug triggers the recurrence. Is this inference actually correct, …
TWiV 954: Speculating sarbecovirus spillovers with Michael Letko
By Vincent Racaniello | | This Week in Virology
Michael Letko joins TWiV to discuss his research on understanding cell receptors required for sarbecovirus entry, including an ACE2-dependent isolate from Russian bats that is resistant to vaccine-induced antibodies.
TWiV 953: Clinical update with Dr. Daniel Griffin
By Vincent Racaniello | | This Week in Virology
In his weekly clinical update Dr. Griffin discusses high demand for Amoxicillin causing shortages amid child RSV surge, epidemiologic and clinical features of children and adolescents aged <18 years with monkeypox, low risk of SARS-Cov-2 transmission by fomites, nucleocapsid antigenemia is a marker of acute SARS-CoV-2 infection, impact of community masking on COVID-19, protection against Omicron from vaccination and …
TWiV 953: Clinical update with Dr. Daniel Griffin Read More »
Jake Scott put the ID in COVID-19
By Vincent Racaniello | | This Week in Virology
Infectious Disease physician Jake Scott joins TWiV to provide a west coast clinical perspective on the evolution of the COVID-19 pandemic with respect to the impact of vaccines, antivirals, variants of concern and mortality. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Kathy Spindler Guest: Jake Scott Click arrow to playDownload TWiV 952 (63 MB .mp3, 104 …
TWiV 951: Clinical update with Dr. Daniel Griffin
By Vincent Racaniello | | This Week in Virology
In his weekly clinical update Dr. Griffin discusses Influenza incidence and vaccine effectiveness during the southern hemisphere influenza season in Chile, Nirsevimab for prevention of RSV infection in healthy late-preterm and term infants, severe Monkeypox in hospitalized patients, reinfections with different SARS-CoV-2 Omicron subvariants, impact of community masking on COVID-19 in Bangladesh, unadjuvanted intranasal spike vaccine elicits protective …
TWiV 951: Clinical update with Dr. Daniel Griffin Read More »
Antibodies Against SARS-CoV-2 Nucleocapsid Protein May Not Be Reliable Markers for Infection in Vaccinated People
By Gertrud U. Rey | | Basic virology, Gertrud Rey
by Gertrud U. Rey You are fully vaccinated against SARS-CoV-2 and have presumably never been infected with the virus. But how can you know for sure? One way to find out is by testing your blood for the presence of antibodies against the viral nucleocapsid protein, which can only be encountered during natural infection. This …
David Tuller
Trial By Error: My Letter to Lead REGAIN Trial Investigator Seeking Correction of Bogus Claims of Clinical Effectiveness
By David Tuller, DrPH Two weeks ago, I sent a letter to The BMJ on behalf of myself and 12 colleagues seeking a correction in a study published last month. The study, called Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial,” claimed that the intervention …
Trial By Error: We Asked BMJ to Correct a Paper; BMJ Requested a Rapid Response; We Have Declined
Leave a Comment / By David Tuller / 24 March 2024 By David Tuller, DrPH Two weeks ago, I sent a letter to The BMJ on behalf of myself and 12 colleagues seeking a correction in a study published last month. The study, called Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): …
Trial By Error: David Putrino on 1) Australian Call to Scrap the Term “Long Covid” and 2) New Pre-Print on Sex Differences in LC
By David Tuller, DrPH Last week, just in time for Long Covid Awareness Day on Friday, the chief health officer of the Australian state of Queensland, John Gerrard, declared that the term “Long Covid” should be dropped. He based his argument on Queensland survey data suggesting that rates of prolonged disability after Covid-19 are similar …
Trial By Error: Professor Chris Ponting on the NIH’s Findings and the Latest on the Genome-Wide Association Study Update
By David Tuller, DrPH When the US National Institutes of Health released its lengthy ME/CFS study last month with much fanfare and publicity, the London-based Science Media Centre asked Professor Chris Ponting, among other experts, to provide comment. The study–“Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome”–was published by Nature Communications. It included in-depth findings …
Trial By Error: Guardian Columnist George Monbiot Calls Out the GET/CBT Charlatans and the Fraudulent PACE Trial
By David Tuller, DrPH In a blistering take-down published on Tuesday, Guardian columnist George Monbiot indicted Professor Sir Simon Wessely, Professor Michael Sharpe and the rest of the GET/CBT ideological brigades for their decades-long promotion of discredited theories about and bogus research into the cluster of illnesses now being called ME/CFS. Those theories and research …
Trial By Error: Letter to BMJ Seeking Correction in Study of Long Covid Physical-and-Mental Rehabilitation Program
By David Tuller, DrPH Last month, The BMJ published a study of a rehab intervention for Long Covid in which the authors made claims that were not borne out by the data. The study was called “Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN …